These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36155169)

  • 1. Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma.
    Talukder R; Makrakis D; Lin GI; Diamantopoulos LN; Dawsey S; Gupta S; Carril-Ajuria L; Castellano D; de Kouchkovsky I; Jindal T; Koshkin VS; Park JJ; Alva A; Bilen MA; Stewart TF; McKay RR; Tripathi N; Agarwal N; Vather-Wu N; Zakharia Y; Morales-Barrera R; Devitt ME; Cortellini A; Fulgenzi CAM; Pinato DJ; Nelson A; Hoimes CJ; Gupta K; Gartrell BA; Sankin A; Tripathi A; Zakopoulou R; Bamias A; Murgic J; Fröbe A; Rodriguez-Vida A; Drakaki A; Liu S; Lu E; Kumar V; Lorenzo GD; Joshi M; Isaacsson-Velho P; Buznego LA; Duran I; Moses M; Barata P; Sonpavde G; Wright JL; Yu EY; Montgomery RB; Hsieh AC; Grivas P; Khaki AR
    Clin Genitourin Cancer; 2022 Dec; 20(6):558-567. PubMed ID: 36155169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
    Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
    Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma.
    Makrakis D; Talukder R; Lin GI; Diamantopoulos LN; Dawsey S; Gupta S; Carril-Ajuria L; Castellano D; de Kouchkovsky I; Koshkin VS; Park JJ; Alva A; Bilen MA; Stewart TF; McKay RR; Tripathi N; Agarwal N; Vather-Wu N; Zakharia Y; Morales-Barrera R; Devitt ME; Cortellini A; Fulgenzi CAM; Pinato DJ; Nelson A; Hoimes CJ; Gupta K; Gartrell BA; Sankin A; Tripathi A; Zakopoulou R; Bamias A; Murgic J; Fröbe A; Rodriguez-Vida A; Drakaki A; Liu S; Lu E; Kumar V; Lorenzo GD; Joshi M; Isaacsson-Velho P; Buznego LA; Duran I; Moses M; Jang A; Barata P; Sonpavde G; Yu EY; Montgomery RB; Grivas P; Khaki AR
    Clin Genitourin Cancer; 2022 Oct; 20(5):e440-e452. PubMed ID: 35778337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy of immune checkpoint inhibitors therapy versus chemotherapy in the treatment of advanced and metastatic urothelial carcinoma: a meta-analysis.
    Huang G; Xiong H; Li S; Zhu Y; Liu H
    J Cancer Res Clin Oncol; 2024 Jan; 150(1):5. PubMed ID: 38170235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response and Outcomes of Maintenance Avelumab After Platinum-Based Chemotherapy (PBC) in Patients With Advanced Urothelial Carcinoma (aUC): "Real World" Experience.
    Bakaloudi DR; Talukder R; Lin GI; Makrakis D; Diamantopoulos LN; Tripathi N; Agarwal N; Zakopoulou R; Bamias A; Brown JR; Pinato DJ; Korolewicz J; Jindal T; Koshkin VS; Murgić J; Miletić M; Frobe A; Johnson J; Zakharia Y; Drakaki A; Rodriguez-Vida A; Rey-Cárdenas M; Castellano D; Buznego LA; Duran I; Carballeira CC; Barrera RM; Marmorejo D; McKay RR; Stewart T; Gupta S; Ruplin AT; Yu EY; Khaki AR; Grivas P
    Clin Genitourin Cancer; 2023 Oct; 21(5):584-593. PubMed ID: 37414620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of first-line chemotherapy regimen on survival outcomes of patients with advanced urothelial carcinoma who received second-line immune checkpoint inhibitors.
    Miron B; Handorf E; Zarrabi K; Zibelman MR; Anari F; Ghatalia P; Plimack ER; Geynisman DM
    Urol Oncol; 2022 Oct; 40(10):454.e9-454.e16. PubMed ID: 35788287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Difference of oncological efficacy between two immune checkpoint inhibitors following first-line platinum-based chemotherapy in patients with unresectable, metastatic, advanced urothelial carcinoma: a multicenter real-world Japanese cohort.
    Miyake M; Nishimura N; Oda Y; Miyamoto T; Iida K; Inoue K; Tachibana A; Yoshikawa T; Sakamoto K; Ohnishi M; Maesaka F; Takamatsu N; Mieda K; Ohmori C; Matsubara T; Tomizawa M; Shimizu T; Ohnishi K; Hori S; Morizawa Y; Gotoh D; Nakai Y; Torimoto K; Tanaka N; Fujimoto K;
    Int J Clin Oncol; 2024 Sep; 29(9):1311-1325. PubMed ID: 38888683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin.
    Talukder R; Makrakis D; Diamantopoulos LN; Carril-Ajuria L; Castellano D; De Kouchkovsky I; Koshkin VS; Park JJ; Alva A; Bilen MA; Stewart TF; McKay RR; Santos VS; Agarwal N; Jain J; Zakharia Y; Morales-Barrera R; Devitt ME; Grant M; Lythgoe MP; Pinato DJ; Nelson A; Hoimes CJ; Shreck E; Gartrell BA; Sankin A; Tripathi A; Zakopoulou R; Bamias A; Murgic J; Fröbe A; Rodriguez-Vida A; Drakaki A; Liu S; Kumar V; Lorenzo GD; Joshi M; Velho PI; Buznego LA; Duran I; Moses M; Barata P; Sonpavde G; Yu EY; Wright JL; Grivas P; Khaki AR
    Clin Genitourin Cancer; 2022 Apr; 20(2):165-175. PubMed ID: 35078711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes.
    Esagian SM; Khaki AR; Diamantopoulos LN; Carril-Ajuria L; Castellano D; De Kouchkovsky I; Park JJ; Alva A; Bilen MA; Stewart TF; McKay RR; Santos VS; Agarwal N; Jain J; Zakharia Y; Morales-Barrera R; Devitt ME; Nelson A; Hoimes CJ; Shreck E; Gartrell BA; Sankin A; Tripathi A; Zakopoulou R; Bamias A; Rodriguez-Vida A; Drakaki A; Liu S; Kumar V; Lythgoe MP; Pinato DJ; Murgic J; Fröbe A; Joshi M; Isaacsson Velho P; Hahn N; Alonso Buznego L; Duran I; Moses M; Barata P; Galsky MD; Sonpavde G; Yu EY; Msaouel P; Koshkin VS; Grivas P
    BJU Int; 2021 Aug; 128(2):196-205. PubMed ID: 33556233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors.
    Khaki AR; Li A; Diamantopoulos LN; Miller NJ; Carril-Ajuria L; Castellano D; De Kouchkovsky I; Koshkin V; Park J; Alva A; Bilen MA; Stewart T; Santos V; Agarwal N; Jain J; Zakharia Y; Morales-Barrera R; Devitt M; Nelson A; Hoimes CJ; Shreck E; Gartrell BA; Sankin A; Tripathi A; Zakopoulou R; Bamias A; Rodriguez-Vida A; Drakaki A; Liu S; Kumar V; Lythgoe MP; Pinato DJ; Murgic J; Fröbe A; Joshi M; Isaacsson Velho P; Hahn N; Alonso Buznego L; Duran I; Moses M; Barata P; Galsky MD; Sonpavde G; Yu EY; Shankaran V; Lyman GH; Grivas P
    Eur Urol Oncol; 2021 Jun; 4(3):464-472. PubMed ID: 33423945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis.
    Mori K; Pradere B; Moschini M; Mostafaei H; Laukhtina E; Schuettfort VM; Sari Motlagh R; Soria F; Teoh JYC; Egawa S; Powles T; Shariat SF;
    Eur J Cancer; 2021 Jul; 151():35-48. PubMed ID: 33962359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-line Chemotherapy Response Is Associated With Clinical Outcome During Immune Checkpoint Inhibitor Treatment in Advanced Urothelial Carcinoma: A Real World Retrospective Study.
    Li JR; Wang SS; Lu K; Chen CS; Cheng CL; Hung SC; Chiu KY; Hsu CY; Yang CK
    Anticancer Res; 2023 Mar; 43(3):1331-1339. PubMed ID: 36854504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The outcome of advanced and recurrent cervical cancer patients treated with first-line platinum and paclitaxel with or without indication for immune checkpoint inhibitors: the comparative study.
    Feng L; Shi Q; Wang S; Zhao Y; Wu H; Wei L; Hao Q; Cui Z; Wang L; Zhang J; Zhang D; Zhan X; Jiang J
    BMC Cancer; 2024 Oct; 24(1):1267. PubMed ID: 39394089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes for immune checkpoint inhibitors plus chemotherapy in non-small-cell lung cancer patients with uncommon driver gene alterations.
    Qin H; Yan H; Chen Y; Xu Q; Huang Z; Jiang W; Wang Z; Deng L; Zhang X; Zhang L; Yang N; Zeng L; Zhang Y
    BMC Cancer; 2024 Aug; 24(1):952. PubMed ID: 39097705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sex hormones influence survival of patients with metastatic urothelial carcinoma undergoing immune checkpoint therapy.
    Lindner AK; Lackner F; Tymoszuk P; Barth DA; Seeber A; Kocher F; Toth B; Hochleitner M; Pichler M; Pichler R
    Biol Sex Differ; 2023 Jun; 14(1):38. PubMed ID: 37277835
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    de Kouchkovsky I; Zhang L; Philip EJ; Wright F; Kim DM; Natesan D; Kwon D; Ho H; Ho S; Chan E; Porten SP; Wong AC; Desai A; Huang FW; Chou J; Oh DY; Pruthi RS; Fong L; Small EJ; Friedlander TW; Koshkin VS
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33980590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and safety of immune checkpoint inhibitor monotherapy in advanced upper tract urothelial carcinoma: A multicenter, retrospective, real-world study.
    Su R; Chen Z; Hong D; Jiang S; Yuan Y; Cai X; Hu H; Fu C; Huang Z; Wang Z; Zheng B; Huang J; Wang Z; Bao Y; Cai M; Guo J; Chen M; Wei Q; Huang J; Xue W
    Cancer Med; 2023 May; 12(9):10587-10596. PubMed ID: 36952461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study).
    Bersanelli M; Buti S; Cortellini A; Bandini M; Banna GL; Pederzoli F; Farè E; Raggi D; Giannatempo P; De Giorgi U; Basso U; Losanno T; Santini D; Mucciarini C; Tucci M; Tambaro R; Farnesi A; Caffo O; Veccia A; Naglieri E; Briganti A; Procopio G; Pignata S; Necchi A
    Clin Med Insights Oncol; 2021; 15():11795549211021667. PubMed ID: 34290538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.